Key Highlights
- Research and development expenses were USD 56.5 million, compared with USD 33 million.
- General and administrative expenses were USD 19.2 million, compared with USD 7.7 million.
- Cash, equivalents and marketable securities were approximately USD 442.3 million.
- FORTIFI-HN01 achieved substantial enrollment for the topline interim analysis.
Bicara Therapeutics Inc. (NASDAQ:BCAX) reported third quarter 2026 Research and Development expenses of USD 56.5 million, compared with USD 33 million in the third quarter of 2025. The company attributed the increase primarily to the ongoing FORTIFI-HN01 pivotal trial, the FORTIFI-FLEX trial, the Phase I/Ib dose expansion cohorts and higher personnel costs. Reported EPS was negative USD 1.04, compared with an estimate of negative USD 0.82.
General and administrative expenses were USD 19.2 million, compared with USD 7.7 million a year earlier. The company ended the quarter with approximately USD 442.3 million in cash, cash equivalents and marketable securities, which it said provides runway into the first half of 2029.
Pivotal Study Progress
Interim chief executive Ryan Cohlhepp said FORTIFI-HN01 has achieved substantial enrollment to enable the topline interim analysis, which the company continues to project for the middle of next year. The study evaluates ficerafusp alfa, known as FICERA, in combination with pembrolizumab in frontline recurrent or metastatic HPV-negative head and neck cancer.
The runway covers advancing the pivotal study through a final overall survival analysis, supporting a planned regulatory filing, and initial Investment in medical and commercial infrastructure ahead of a potential U.S. launch. Management said its commercial Leadership team, with more than 50 collective new product launches, is in place.
Phase Ib Data Review
Management reviewed long-term Phase Ib data presented at ASCO this year. At the 1,500 mg weekly pivotal dose with a median follow-up of 3 years, FICERA plus pembrolizumab achieved a confirmed objective response rate of 54% and a complete response rate of 25%. Of responders, 80% had tumor shrinkage of 80% or more. Responses came at a median of about 6 weeks and had a median duration of response of nearly 22 months.
Median progression-free survival was 9.9 months, which management said is roughly three times what has been reported for pembrolizumab alone, and median overall survival was just over 21 months. About one in three patients was alive at 3 years. Pooled across all three dose cohorts, patients with deep responses remained in response for a median of more than 2.5 years. Paired biopsies showed reduced TGF-beta signaling in the tumor and greater CD8 T cell infiltration.
Every patient in the Phase Ib data set was HPV negative, the only population enrolled in FORTIFI-HN01. Half of the Phase Ib patients had a CPS below 20, and management said responses were essentially the same regardless of CPS.
Market Context
Management cited roughly 50,000 patients newly diagnosed each year with HPV-negative disease across the U.S., EU5 and Japan, about 18,000 of them in the U.S. HPV-negative disease represents roughly 80% to 90% of cases globally. The head and neck cancer market is projected to reach more than USD 5 billion globally by 2030.
Interim Analysis Timing and Cash Runway
Bicara's pivotal FORTIFI-HN01 study reached substantial enrollment for the topline interim analysis, which the company placed in the middle of next year. Cash, equivalents and marketable securities of approximately USD 442.3 million were cited as covering operations into the first half of 2029, while research and development expense of USD 56.5 million reflects the pivotal and FORTIFI-FLEX trials. The company reported no revenue.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...